NIKKEI 225
38,118.99 -286.67 (-0.75%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.11 -0.82 (-1.00%) GOLD FUTURES
2,297.80 -5.10 (-0.22%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
47,929.08 -3,188.58 (-6.24%)
NVO Jan 2026 67.500 put
| Previous close | 1.8000 |
| Open | 1.8000 |
| Bid | 1.7000 |
| Ask | 2.7200 |
| Strike | 67.50 |
| Expiry date | 2026-01-16 |
| Day's range | 1.8000 - 1.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 12 |
Yahoo FinanceEli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Investor's Business DailyIBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.
BloombergOzempic Maker Novo Nordisk Has Denmark’s Economy Hooked
(Bloomberg) -- There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global phenomenon. They’ve won over the rich and famous, generated billions in sales and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030.Most Read from BloombergHSBC CEO Quinn Unexpectedly Steps Down After Almost 5 YearsWall Street Hit by Fed Jitters to Close Wild April: Markets WrapBinance and CZ’s Fortunes Are Set to Grow, Even in Jail
